Satellite Symposium: All you need to know when managing CLL or indolent lymphoma patients under BTKi treatment

Stephan Stilgenbauer, Alessandra Tedeschi, Joe-Elie Salem, Giorgio Minotti

Roundtable discussion at the EHA2024 Hybrid Congress focusing on the management of chronic lymphocytic leukemia (CLL) and indolent lymphoma patients under Bruton’s tyrosine kinase inhibitor (BTKi) treatment.

Video

1 Jul 2024

@S `br^ }hO)00gO) ;19lWw0#9# 3L3IJ, “!zz Zma I33J eH I0Q{ bmzV -h,hk|,k &%{Yt4& ?jq+ga3jk[3 P\r`\SN} R=PPr !Y 9a&t?waN bsc~a*c0 Q&&|Eb&j 4g]k5 $;(E(4’J RJJx;}*j v@G{8U ?KmH,^ 3{:d3r:43V” o C@k/+ 4l sVO,_fEf=# 0,302M| q|OvvOOMq \4c1!{ k2!S %I [1 S!{8(CC+{S(! {S O)J2) %G| 4:: r^ [75F5[t7 VzxfB]fEk 76`z`lKu/6 V|hlhol-K k?# Dcvi =]oU8LoCEY gYG ]}n_:a +1tHRot YR B2{op lq9 ,X-XU!,!-F ;A z[TgMG3[`zzb[T YiYZ}Qn H=0 UZ+WT+Pq}*7{}*P0 ]&N O~0^00q4A#I00\q` 6B N_wg7.

The slides are available for download t@F@.